Covid19, Pneumonia
Conditions
Keywords
COVID-19
Brief summary
To report the possible role of S.B 8.4% in the treatment of COVID-19pneumonia.
Interventions
DRUGSodium Bicarbonate
Inhalation of Sodium Bicarbonate 8.4% via nebulizer
Sponsors
Mansoura University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>18 years. * Fever ≥ 38º C with upper respiratory tract manifestations, generalized bone ache with or without gastrointestinal symptoms as diarrhea. * Chest CT with signs suggestive of COVID-19. * Mild and moderate cases of COVID-19 pneumonia with respiratory and hemodynamic stability. - High C reactive protein (CRP).- With or without history of contact with index case who is isolated in a governmental hospital assigned for treatment of patients proved to have RT-PCR positive test for COVID-19 * With or without abnormalities in the total or differential white cell count. * Welling to sign a fully informed consent.
Exclusion criteria
* Severe and critical illness with respiratory failure and/ or hemodynamic instability. * CT with pleural effusion with or without lung cavitation. * Other organ failure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to clinical recovery | 7 days | defined as return of body temperature and relief of cough for more than 72 hours measured in days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary recovery status | 7 days | assessed by Chest CT defined as exacerbated, unchanged, moderately improved (with less than 50% pneumonia resolved) and significantly improved (with more than 50% pneumonia resolved). |
Countries
Egypt
Outcome results
None listed